**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (currently amended): A pyrazole derivative represented by the following general formula (~~I~~)(Iα):




(Iα)

wherein

$R^1$ represents a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

one of $Q^0$ and $T^0$ represents a group selected from


and , and the

other represents a group represented by the formula: $-(CH_2)_n$-Ar wherein Ar represents a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B) or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B); and n represents an integral number from 0 to 2, a $C_{1-6}$ alkoxy group which may have the same or different 1 to 3 groups selected from the following substituent group (A), an optionally mono or di($C_{1-6}$ alkyl)-substituted amino group wherein the $C_{1-6}$ alkyl group may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

R represents a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

[substituent group (A)]:

a halogen atom, a nitro group, a cyano group, an oxo group,$-G^1$, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-C(=O)G^2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2G^2$, $-S(=O)_2OG^2$, $-S(=O)_2N(G^2)_2$, $-S(=O)G^1$, -

$OC(=O)G^1$, $-OC(=O)N(G^2)_2$, $-NHC(=O)G^2$, $-OS(=O)_2G^1$, $-NHS(=O)_2G^1$ and $-C(=O)NHS(=O)_2G^1$;

[substituent group (B)]:

a halogen atom, a nitro group, a cyano group, $-G^1$, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-G^3OG^4$, $-G^3N(G^4)_2$, $-C(=O)G^2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2G^2$, $-S(=O)_2OG^2$, $-S(=O)_2N(G^2)_2$, $-S(=O)G^1$, $-OC(=O)G^1$, $-OC(=O)N(G^2)_2$, $-NHC(=O)G^2$, $-OS(=O)_2G^1$, $-NHS(=O)_2G^1$ and $-C(=O)NHS(=O)_2G^1$;

in the above substituent group (A) and/or (B),

$G^1$ represents a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D);

$G^2$ represents a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3

groups selected from the following substituent group (C), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), and with the proviso that $G^2$ may be the same or different when there are 2 or more $G^2$ in the substituents;

$G^3$ represents a $C_{1-6}$ alkyl group;

$G^4$ represents a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), and with the proviso that $G^4$ may be the same or different when there are 2 or more $G^4$ in the substituents;

[substituent group (C)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^5$, $-OG^6$, $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^6)_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$; and

[substituent group (D)]:

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^6$, $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^6)_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$;

in the substituent group (C) and/or (D),

$G^5$ represents a $C_{1-6}$ alkyl group, a $C_{2-6}$ alkenyl group, a $C_{2-6}$ alkynyl, a $C_{3-8}$ cycloalkyl group, a $C_{6-10}$ aryl group, a $C_{2-9}$ heterocycloalkyl group or a $C_{1-9}$ heteroaryl group; and

$G^6$ represents a hydrogen atom, a $C_{1-6}$ alkyl group, a $C_{2-6}$ alkenyl group, a $C_{2-6}$ alkynyl, a $C_{3-8}$ cycloalkyl group, a $C_{6-10}$ aryl group, a $C_{2-9}$ heterocycloalkyl group or a $C_{1-9}$ heteroaryl group, and with the proviso that $G^6$ may be the same or different when there are 2 or more $G^6$ in the substituents, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

2. (original): A pyrazole derivative as claimed in claim 1, wherein

$R^1$ represents a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the substituent group (A), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the substituent group (A), or a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the substituent group (B); $Q^0$ represents a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the substituent group (B); $T^0$ represents a group:



;

R represents a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the substituent group (B); substituent group (A) consists of a halogen atom, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2OG^2$ and $-S(=O)_2N(G^2)_2$ in which $G^2$ represents a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the substituent group (C); or a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the substituent group (D); and substituent group (B) consists of a halogen atom, a nitro group, a cyano group, $-G^1$, $-OG^2$, $-SG^2$, $-C(=O)OG^2$ in which

$G^1$ represents a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the substituent group (C) or a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the substituent group (D); and $G^2$ has the same meaning as defined above, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

3. (original): A pyrazole derivative as claimed in claim 1, wherein one of $Q^0$ and $T^0$ represents a group selected from




, and the other represents a group represented by the formula: $-(CH_2)_n$-Ar, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

4. (original): A pyrazole derivative as claimed in claim 3, wherein wherein $Q^0$ represents a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the substituent group (B); $T^0$ represents a group selected from




, and R represents a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the substituent group (B), or a pharmaceutically acceptable salt thereof or a prodrug thereof.

5. (original): A pyrazole derivative as claimed in claim 4, wherein $T^0$ represents a group:



and substituent group (B) consists of a halogen atom, a nitro group, a cyano group, $-G^1$, $-OG^2$, $-SG^2$ and $-C(=O)OG^2$ in which $G^1$ represents a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the substituent group (C) or a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the substituent group (D); and $G^2$ represents a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the substituent group (C) or a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the substituent group (D), or a pharmaceutically acceptable salt thereof or a prodrug thereof.

6. (original): A pyrazole derivative as claimed in claim 1, wherein one of $Q^0$ and $T^0$ represents a group selected from


and


, and the other represents a $C_{1-6}$ alkoxy group which may have the same or different 1 to 3 groups selected from the substituent group (A), an optionally mono or di($C_{1-6}$ alkyl)-substituted amino group in

which the $C_{1-6}$ alkyl group may have the same or different 1 to 3 groups selected from the substituent group (A), or a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the substituent group (A), or a pharmaceutically acceptable salt thereof or a prodrug thereof.

7. (original): A pyrazole derivative as claimed in claim 6, wherein $Q^0$ represents an optionally mono or di($C_{1-6}$ alkyl)-substituted amino group in which the $C_{1-6}$ alkyl group may have the same or different 1 to 3 groups selected from the substituent group (A), or a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the substituent group (A); and $T^0$ represents a group selected from




, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

8. (original): A pyrazole derivative as claimed in claim 1, wherein one of $Q^0$ and $T^0$ represents a group selected from




, and the other represents a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the substituent group (B), or a pharmaceutically acceptable salt thereof or a prodrug thereof.

9. (original): A pyrazole derivative as claimed in claim 8, wherein $Q^0$ represents a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the substituent group (B); and $T^0$ represents a group selected from




, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

10. (previously presented): A pharmaceutical composition comprising as an active ingredient a pyrazole derivative as claimed in claim 1, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

11. (currently amended): ~~An inhibitor of 1,5-anhydroglucitol/fructose/mannose transporter comprising as an active ingredient~~ A method for inhibiting 1,5-anhydroglucitol/fructose/mannose transporter activity, which comprises administering to a subject in need thereof an effective amount of a pyrazole derivative represented by the following general formula (I):




(I)

wherein

$R^1$ represents a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{2-6}$ alkenyl group which may

have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

one of Q and T represents a group selected from


,

,

,

and

, and the

other represents a group represented by the formula: $-(CH_2)_n$-Ar wherein Ar represents a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B) or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B); and n represents an integral number from 0 to 2, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{1-6}$ alkoxy group which may have the same or different 1 to 3 groups selected from the following substituent group (A), an optionally mono or di($C_{1-6}$ alkyl)-substituted amino group wherein the $C_{1-6}$ alkyl group may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{2-9}$

heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

R represents a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

[substituent group (A)]:

a halogen atom, a nitro group, a cyano group, an oxo group,$-G^1$, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-C(=O)G^2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2G^2$, $-S(=O)_2OG^2$, $-S(=O)_2N(G^2)_2$, $-S(=O)G^1$, $-OC(=O)G^1$, $-OC(=O)N(G^2)_2$, $-NHC(=O)G^2$, $-OS(=O)_2G^1$, $-NHS(=O)_2G^1$ and $-C(=O)NHS(=O)_2G^1$;

[substituent group (B)]:

a halogen atom, a nitro group, a cyano group, $-G^1$, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-G^3OG^4$, $-G^3N(G^4)_2$, $-C(=O)G^2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2G^2$, $-S(=O)_2OG^2$, $-S(=O)_2N(G^2)_2$, $-S(=O)G^1$, $-OC(=O)G^1$, $-OC(=O)N(G^2)_2$, $-NHC(=O)G^2$, $-OS(=O)_2G^1$, $-NHS(=O)_2G^1$ and $-C(=O)NHS(=O)_2G^1$;

in the above substituent group (A) and/or (B),

$G^1$ represents a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{2-6}$ alkynyl group

which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D);

$G^2$ represents a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), and with the proviso that $G^2$ may be the same or different when there are 2 or more $G^2$ in the substituents;

$G^3$ represents a $C_{1-6}$ alkyl group;

$G^4$ represents a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), and with the proviso that $G^4$ may be the same or different when there are 2 or more $G^4$ in the substituents;

[substituent group (C)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^5$, $-OG^6$, $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^6)_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$; and

[substituent group (D)]:

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^6$, $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^6)_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$;

in the substituent group (C) and/or (D),

$G^5$ represents a $C_{1-6}$ alkyl group, a $C_{2-6}$ alkenyl group, a $C_{2-6}$ alkynyl, a $C_{3-8}$ cycloalkyl group, a $C_{6-10}$ aryl group, a $C_{2-9}$ heterocycloalkyl group or a $C_{1-9}$ heteroaryl group; and

$G^6$ represents a hydrogen atom, a $C_{1-6}$ alkyl group, a $C_{2-6}$ alkenyl group, a $C_{2-6}$ alkynyl, a $C_{3-8}$ cycloalkyl group, a $C_{6-10}$ aryl group, a $C_{2-9}$ heterocycloalkyl group or a $C_{1-9}$ heteroaryl group, and with the proviso that $G^6$ may be the same or different when there are 2 or more $G^6$ in the substituents, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

12. (currently amended): ~~An inhibitor of 1,5-anhydroglucitol/fructose/mannose transporter comprising as an active ingredient~~ A method for inhibiting 1,5-anhydroglucitol/fructose/mannose transporter activity, which comprises administering to a subject in need thereof an effective amount of a pyrazole derivative as claimed in claim 1, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

13. (currently amended): ~~An agent as claimed in claim 11, which is an agent for the prevention, inhibition of progression or~~ A method for treatment of a disease associated with the excess uptake of at least a kind of ~~carbohydrates~~ carbohydrate selected from glucose, fructose and mannose, which comprises administering to a subject in need thereof an effective amount of a pyrazole derivative represented by the following general formula (I):



(I)

wherein

$R^1$ represents a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

one of Q and T represents a group selected from



and the other represents a group represented by the formula: -$(CH_2)_n$-Ar wherein Ar represents a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B) or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B); and n represents an integral number from 0 to 2, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{1-6}$ alkoxy group which may have the same or different 1 to 3 groups selected from the following substituent group (A), an optionally mono or di($C_{1-6}$ alkyl)-substituted amino group wherein the $C_{1-6}$ alkyl group may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

R represents a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

[substituent group (A)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^1$, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-C(=O)G^2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2G^2$, $-S(=O)_2OG^2$, $-S(=O)_2N(G^2)_2$, $-S(=O)G^1$, $-OC(=O)G^1$, $-OC(=O)N(G^2)_2$, $-NHC(=O)G^2$, $-OS(=O)_2G^1$, $-NHS(=O)_2G^1$ and $-C(=O)NHS(=O)_2G^1$;

[substituent group (B)]:

a halogen atom, a nitro group, a cyano group, $-G^1$, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-G^3OG^4$, $-G^3N(G^4)_2$, $-C(=O)G^2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2G^2$, $-S(=O)_2OG^2$, $-S(=O)_2N(G^2)_2$, $-S(=O)G^1$, $-OC(=O)G^1$, $-OC(=O)N(G^2)_2$, $-NHC(=O)G^2$, $-OS(=O)_2G^1$, $-NHS(=O)_2G^1$ and $-C(=O)NHS(=O)_2G^1$;

in the above substituent group (A) and/or (B),

$G^1$ represents a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D);

$G^2$ represents a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{2-6}$

alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), and with the proviso that $G^2$ may be the same or different when there are 2 or more $G^2$ in the substituents;

$G^3$ represents a $C_{1-6}$ alkyl group;

$G^4$ represents a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), and with the proviso that $G^4$ may be the same or different when there are 2 or more $G^4$ in the substituents;

[substituent group (C)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^5$, $-OG^6$, $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^6)_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$; and

[substituent group (D)]:

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^6$, $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^6)_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$;

in the substituent group (C) and/or (D),

$G^5$ represents a $C_{1-6}$ alkyl group, a $C_{2-6}$ alkenyl group, a $C_{2-6}$ alkynyl, a $C_{3-8}$ cycloalkyl group, a $C_{6-10}$ aryl group, a $C_{2-9}$ heterocycloalkyl group or a $C_{1-9}$ heteroaryl group; and

$G^6$ represents a hydrogen atom, a $C_{1-6}$ alkyl group, a $C_{2-6}$ alkenyl group, a $C_{2-6}$ alkynyl, a $C_{3-8}$ cycloalkyl group, a $C_{6-10}$ aryl group, a $C_{2-9}$ heterocycloalkyl group or a $C_{1-9}$ heteroaryl group, and with the proviso that $G^6$ may be the same or different when there are 2 or more $G^6$ in the substituents, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

14. (currently amended): ~~An agent for the prevention, inhibition of progression or~~ A method for the treatment of a disease associated with the excess uptake of at least a kind of ~~carbohydrates~~ carbohydrate selected from glucose, fructose and mannose, which comprises administering to a subject in need thereof an effective amount of ~~comprising as an active ingredient~~ a pyrazole derivative as claimed in claim 1, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

15. (currently amended): ~~An agent~~ A method as claimed in claim 13, wherein the disease associated with the excess uptake of at least a kind of ~~carbohydrates~~ carbohydrate selected from glucose, fructose and mannose is diabetic complications.

16. (currently amended): ~~An agent~~ A method as claimed in claim 14, wherein the disease associated with the excess uptake of at least a kind of ~~carbohydrates~~ carbohydrate selected from glucose, fructose and mannose is diabetic complications.

17. (currently amended): ~~An agent~~ A method as claimed in claim 15, wherein the diabetic complications is diabetic nephropathy.

18. (currently amended): ~~An agent~~ A method as claimed in claim 16, wherein the diabetic complications is diabetic nephropathy.

19. (currently amended): ~~An agent~~ A method as claimed in claim 13, wherein the disease associated with the excess uptake of at least a kind of ~~carbohydrates~~ carbohydrate selected from glucose, fructose and mannose is diabetes.

20. (currently amended): ~~An agent~~ A method as claimed in claim 14, wherein the disease associated with the excess uptake of at least a kind of ~~carbohydrates~~ carbohydrate selected from glucose, fructose and mannose is diabetes.

21. (previously presented): A pharmaceutical combination which comprises (component a) a pyrazole derivative as claimed in claim 1, or a pharmaceutically acceptable salt thereof or a prodrug thereof, and (component b) at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1

analogue, a glucagon-like peptide-1 agonist, amylin, an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ-aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript factor NF-κB inhibitor, a lipid peroxidase inhibitor, an *N*-acetylated-α-linked-acid-dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine, 5-hydroxy-1-methylhidantoin, EGB-761, bimoclomol, sulodexide, Y-128, a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibric acid derivative, a $\beta_3$-adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an $\alpha_2$-adrenoceptor agonist, an antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer.

22. (original): A pyrazole derivative represented by the following general formula (IIα):


(IIα)

wherein

$R^{1A}$ represents a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

one of $Q^{A0}$ and $T^{A0}$ represents a group selected from


and having

protective group(s), and the other represents a group represented by the formula: $-(CH_2)_n-Ar^A$ wherein $Ar^A$ represents a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1) or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1); and n

represents an integral number from 0 to 2, a $C_{1-6}$ alkoxy group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), an optionally mono or di($C_{1-6}$ alkyl)-substituted amino group wherein the $C_{1-6}$ alkyl group may have the same or different 1 to 3 groups selected from the following substituent group (A1), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

$R^A$ represents a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

[substituent group (A1)]:

a halogen atom, a nitro group, a cyano group, an oxo group,$-G^{1A}$, $-OG^{2B}$, $-SG^{2B}$, $-N(G^{2B})_2$, $-C(=O)G^{2A}$, $-C(=O)OG^{2B}$, $-C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$, $-S(=O)_2N(G^{2B})_2$, $-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$, $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

[substituent group (B1)]:

a halogen atom, a nitro group, a cyano group, $-G^{1A}$, $-OG^{2B}$, $-SG^{2B}$, $-N(G^{2B})_2$, $-G^3OG^{4A}$, $-G^3N(G^{4A})_2$, $-C(=O)G^{2A}$, $-C(=O)OG^{2B}$, $-C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$, $-S(=O)_2N(G^{2B})_2$, $-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$, $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

in the above substituent group (A1) and/or (B1),

$G^{1A}$ represents a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

$G^{2A}$ represents a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

$G^{2B}$ represents a protective group, a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{2-6}$

alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), and with the proviso that $G^{2B}$ may be the same or different when there are 2 or more $G^{2B}$ in the substituents;

$G^3$ represents a $C_{1-6}$ alkyl group;

$G^{4A}$ represents a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), and with the proviso that $G^{4A}$ may be the same or different when there are 2 or more $G^{4A}$ in the substituents;

[substituent group (C1)]:

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^{6A}$, $-SG^{6A}$, $-N(G^{6A})_2$, $-C(=O)G^6$, $-C(=O)OG^{6A}$, $-C(=O)N(G^{6A})_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^{6A})_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^{6A})_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$; and

[substituent group (D1)]:

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^{6A}$, $-SG^{6A}$, $-N(G^{6A})_2$, $-C(=O)G^6$, $-C(=O)OG^{6A}$, $-C(=O)N(G^{6A})_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^{6A})_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^{6A})_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$;

in the substituent group (C1) and/or (D1),

$G^5$ represents a $C_{1-6}$ alkyl group, a $C_{2-6}$ alkenyl group, a $C_{2-6}$ alkynyl, a $C_{3-8}$ cycloalkyl group, a $C_{6-10}$ aryl group, a $C_{2-9}$ heterocycloalkyl group or a $C_{1-9}$ heteroaryl group;

$G^6$ represents a hydrogen atom, a $C_{1-6}$ alkyl group, a $C_{2-6}$ alkenyl group, a $C_{2-6}$ alkynyl, a $C_{3-8}$ cycloalkyl group, a $C_{6-10}$ aryl group, a $C_{2-9}$ heterocycloalkyl group or a $C_{1-9}$ heteroaryl group; and

$G^{6A}$ represents a protective group, a hydrogen atom, a $C_{1-6}$ alkyl group, a $C_{2-6}$ alkenyl group, a $C_{2-6}$ alkynyl, a $C_{3-8}$ cycloalkyl group, a $C_{6-10}$ aryl group, a $C_{2-9}$ heterocycloalkyl group or a $C_{1-9}$ heteroaryl group, and with the proviso that $G^{6A}$ may be the same or different when there are 2 or more $G^{6A}$ in the substituents, or a pharmaceutically acceptable salt thereof.

23. (original): A pyrazole derivative represented by the following general formula (IIIα):



(IIIα)

wherein

$R^{1A}$ represents a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a $C_{6-10}$ aryl group

which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

one of $Q^{B0}$ and $T^{B0}$ represents a hydroxy group, and the other represents a group represented by the formula: $-(CH_2)_n-Ar^A$ wherein $Ar^A$ represents a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1) or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1); and n represents an integral number from 0 to 2, a $C_{1-6}$ alkoxy group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), an optionally mono or di($C_{1-6}$ alkyl)-substituted amino group wherein the $C_{1-6}$ alkyl group may have the same or different 1 to 3 groups selected from the following substituent group (A1), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

$R^A$ represents a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

[substituent group (A1)]:

a halogen atom, a nitro group, a cyano group, an oxo group,-$G^{1A}$, -$OG^{2B}$, -$SG^{2B}$, -$N(G^{2B})_2$, -C(=O)$G^{2A}$, -C(=O)$OG^{2B}$, -C(=O)$N(G^{2B})_2$, -S(=O)$_2G^{2A}$, -S(=O)$_2OG^{2A}$, -S(=O)$_2N(G^{2B})_2$, -S(=O)$G^{1A}$, -OC(=O)$G^{1A}$, -OC(=O)$N(G^{2B})_2$, -NHC(=O)$G^{2A}$, -OS(=O)$_2G^{1A}$, -NHS(=O)$_2G^{1A}$ and –C(=O)NHS(=O)$_2G^{1A}$;

[substituent group (B1)]:

a halogen atom, a nitro group, a cyano group, -$G^{1A}$, -$OG^{2B}$, -$SG^{2B}$, -$N(G^{2B})_2$, -$G^3OG^{4A}$, -$G^3N(G^{4A})_2$, -C(=O)$G^{2A}$, -C(=O)$OG^{2B}$, -C(=O)$N(G^{2B})_2$, -S(=O)$_2G^{2A}$, -S(=O)$_2OG^{2A}$, -S(=O)$_2N(G^{2B})_2$, -S(=O)$G^{1A}$, -OC(=O)$G^{1A}$, -OC(=O)$N(G^{2B})_2$, -NHC(=O)$G^{2A}$, -OS(=O)$_2G^{1A}$, -NHS(=O)$_2G^{1A}$ and –C(=O)NHS(=O)$_2G^{1A}$;

in the above substituent group (A1) and/or (B1),

$G^{1A}$ represents a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

$G^{2A}$ represents a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent

group (C1), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1);

$G^{2B}$ represents a protective group, a hydrogen atom, a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{2-6}$ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{2-6}$ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{3-8}$ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a $C_{6-10}$ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a $C_{2-9}$ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a $C_{1-9}$ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), and with the proviso that $G^{2B}$ may be the same or different when there are 2 or more $G^{2B}$ in the substituents;

$G^3$ represents a $C_{1-6}$ alkyl group;

$G^{4A}$ represents a $C_{1-6}$ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), and with the proviso that $G^{4A}$ may be the same or different when there are 2 or more $G^{4A}$ in the substituents;

[substituent group (C1)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^5$, $-OG^{6A}$, $-SG^{6A}$, $-N(G^{6A})_2$, $-C(=O)G^6$, $-C(=O)OG^{6A}$, $-C(=O)N(G^{6A})_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^{6A})_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^{6A})_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$; and

[substituent group (D1)]:

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^{6A}$, $-SG^{6A}$, $-N(G^{6A})_2$, $-C(=O)G^6$, $-C(=O)OG^{6A}$, $-C(=O)N(G^{6A})_2$, $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^{6A})_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^{6A})_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$;

in the substituent group (C1) and/or (D1),

$G^5$ represents a $C_{1-6}$ alkyl group, a $C_{2-6}$ alkenyl group, a $C_{2-6}$ alkynyl, a $C_{3-8}$ cycloalkyl group, a $C_{6-10}$ aryl group, a $C_{2-9}$ heterocycloalkyl group or a $C_{1-9}$ heteroaryl group;

$G^6$ represents a hydrogen atom, a $C_{1-6}$ alkyl group, a $C_{2-6}$ alkenyl group, a $C_{2-6}$ alkynyl, a $C_{3-8}$ cycloalkyl group, a $C_{6-10}$ aryl group, a $C_{2-9}$ heterocycloalkyl group or a $C_{1-9}$ heteroaryl group; and

$G^{6A}$ represents a protective group, a hydrogen atom, a $C_{1-6}$ alkyl group, a $C_{2-6}$ alkenyl group, a $C_{2-6}$ alkynyl, a $C_{3-8}$ cycloalkyl group, a $C_{6-10}$ aryl group, a $C_{2-9}$ heterocycloalkyl group or a $C_{1-9}$ heteroaryl group, and with the proviso that $G^{6A}$ may be the same or different when there are 2 or more $G^{6A}$ in the substituents, or a pharmaceutically acceptable salt thereof.